Global Biopharmaceutical and Bio-CDMO Competitive Landscape Professional Research Report 2025

Global Biopharmaceutical and Bio-CDMO Competitive Landscape Professional Research Report 2025

Research Summary

Biopharmaceuticals are medical drugs produced using living organisms or biological systems, as opposed to traditional chemically synthesized pharmaceuticals. These drugs include a wide range of products such as monoclonal antibodies, vaccines, recombinant proteins, and gene therapies, which are used to treat various diseases, including cancer, autoimmune disorders, and infectious diseases. Biopharmaceuticals often require complex manufacturing processes involving cell cultures or fermentation. A Bio-CDMO (Biopharmaceutical Contract Development and Manufacturing Organization) is a specialized service provider that assists biopharmaceutical companies in developing and manufacturing these complex biologic drugs. Bio-CDMOs offer a range of services, including process development, scale-up, clinical and commercial production, and regulatory support, helping clients bring biopharmaceutical products to market more efficiently and cost-effectively. These organizations provide expertise in areas such as biologic formulation, purification, and quality control, ensuring that biopharmaceuticals are produced at high quality and in compliance with regulatory standards, often for clients who lack the resources or facilities to handle production in-house.

According to DIResearch's in-depth investigation and research, the global Biopharmaceutical and Bio-CDMO market size was valued at XX Million USD in 2024 and is projected to reach XX Million USD by 2032, with a CAGR of XX% (2025-2032). Notably, the China market has changed rapidly in the past few years. By 2024, China's market size is expected to be XX Million USD, representing approximately XX% of the global market share. By 2032, it is anticipated to grow further to XX Million USD, contributing XX% to the worldwide market share.

The major global  manufacturers of Biopharmaceutical and Bio-CDMO include Lonza, Catalent, Samsung Biologics, FUJIFILM Diosynth Biotechnologies, Boehringer Ingelheim, WuXi Biologics, Recipharm, Thermo Fisher Scientific, AGC Biologics, Rentschler Biopharma, KBI Biopharma, Siegfried, Aenova Group, GenScript, ProBioGen, Northway Biotech, 3P Biopharmaceuticals etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.

This report studies the market size, price trends and future development prospects of Biopharmaceutical and Bio-CDMO. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major manufacturers, as well as the market status and trends of different product types and applications in the global Biopharmaceutical and Bio-CDMO market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.

The regions and countries in the report include North America, Europe, China, APAC (excl. China), Latin America and Middle East and Africa, covering the Biopharmaceutical and Bio-CDMO market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Biopharmaceutical and Bio-CDMO industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.  

The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.

Global Key Manufacturers of Biopharmaceutical and Bio-CDMO Include:

Lonza

Catalent

Samsung Biologics

FUJIFILM Diosynth Biotechnologies

Boehringer Ingelheim

WuXi Biologics

Recipharm

Thermo Fisher Scientific

AGC Biologics

Rentschler Biopharma

KBI Biopharma

Siegfried

Aenova Group

GenScript

ProBioGen

Northway Biotech

3P Biopharmaceuticals

Biopharmaceutical and Bio-CDMO Product Segment Include:

Cell and Gene Therapies

Antibodies

Vaccines

Others

Biopharmaceutical and Bio-CDMO Product Application Include:

SMBs

Large Companies

Chapter Scope

Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trends

Chapter 2: Global Biopharmaceutical and Bio-CDMO Industry PESTEL Analysis

Chapter 3: Global Biopharmaceutical and Bio-CDMO Industry Porter’s Five Forces Analysis

Chapter 4: Global Biopharmaceutical and Bio-CDMO Major Regional Market Size and Forecast Analysis

Chapter 5: Global Biopharmaceutical and Bio-CDMO Market Size and Forecast by Type and Application Analysis

Chapter 6: North America Passenger Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 7: Europe Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 8: China Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 9: APAC (Excl. China) Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 10: Latin America Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 11: Middle East and Africa Biopharmaceutical and Bio-CDMO Competitive Analysis (Market Size, Key Players and Market Share, Product Type and Application Segment Analysis, Countries Analysis)

Chapter 12: Global Biopharmaceutical and Bio-CDMO Competitive Analysis of Key Manufacturers (Revenue, Market Share, Regional Distribution and Industry Concentration)

Chapter 13: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)

Chapter 14: Industrial Chain Analysis, Include Raw Material Suppliers, Distributors and Customers

Chapter 15: Research Findings and Conclusion

Chapter 16: Methodology and Data Sources